OncoSec Medical Inc. (NASDAQ: ONCS) Starts Presentation at NobleCon16
OncoSec Medical (NASDAQ: ONCS) is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec has built a deep and diverse clinical pipeline utilizing its primary technology, TAVO™ (tavokinogene telseplasmid), as a potential treatment for multiple cancer indications, either as a monotherapy or in combination with leading checkpoint inhibitors. The latter potentially enables OncoSec to address a great unmet medical need in oncology: anti-PD-1 non- responders. OncoSec is also identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its new Visceral Lesion Applicator (VLA), to…







